BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

29 related articles for article (PubMed ID: 38428265)

  • 1. Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer.
    Provencio-Pulla M; Pérez-Parente D; Olson S; Hasan H; Balea BC; Rodríguez-Abreu D; Piqueras ML; Pal N; Wilkinson S; Vilas E; Ruiz-Gracia P; Cobo-Dols M
    Clin Transl Oncol; 2024 Jun; 26(6):1384-1394. PubMed ID: 38183584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.
    Schabath MB; Welsh EA; Fulp WJ; Chen L; Teer JK; Thompson ZJ; Engel BE; Xie M; Berglund AE; Creelan BC; Antonia SJ; Gray JE; Eschrich SA; Chen DT; Cress WD; Haura EB; Beg AA
    Oncogene; 2016 Jun; 35(24):3209-16. PubMed ID: 26477306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.
    Whang YM; Park SI; Trenary IA; Egnatchik RA; Fessel JP; Kaufman JM; Carbone DP; Young JD
    Oncogene; 2016 Feb; 35(7):856-66. PubMed ID: 26119936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.
    Caiola E; Salles D; Frapolli R; Lupi M; Rotella G; Ronchi A; Garassino MC; Mattschas N; Colavecchio S; Broggini M; Wiesmüller L; Marabese M
    Oncotarget; 2015 Oct; 6(30):30072-87. PubMed ID: 26353932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Evidence Study of Patients with
    Anttalainen A; Pietarinen P; Tuominen S; Mattila R; Mutka A; Knuuttila A
    Curr Oncol; 2024 May; 31(5):2700-2712. PubMed ID: 38785486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor.
    Gao Y; Ge G; Ji H
    Protein Cell; 2011 Feb; 2(2):99-107. PubMed ID: 21380642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LKB1 Loss Correlates with STING Loss and, in Cooperation with β-Catenin Membranous Loss, Indicates Poor Prognosis in Patients with Operable Non-Small Cell Lung Cancer.
    Lagoudaki ED; Koutsopoulos AV; Sfakianaki M; Papadaki C; Manikis GC; Voutsina A; Trypaki M; Tsakalaki E; Fiolitaki G; Hatzidaki D; Yiachnakis E; Koumaki D; Mavroudis D; Tzardi M; Stathopoulos EN; Marias K; Georgoulias V; Souglakos J
    Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide CRISPR screens in spheroid culture reveal that the tumor suppressor LKB1 inhibits growth via the PIKFYVE lipid kinase.
    Ferrarone JR; Thomas J; Unni AM; Zheng Y; Nagiec MJ; Gardner EE; Mashadova O; Li K; Koundouros N; Montalbano A; Mustafa M; Cantley LC; Blenis J; Sanjana NE; Varmus H
    Proc Natl Acad Sci U S A; 2024 May; 121(21):e2403685121. PubMed ID: 38743625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of KRAS Mutations in Relation to PDL1 Expression and Immunotherapy Treatment in Adenocarcinoma and Squamous Cell Carcinoma Patients: A Greek Cohort Study.
    Tsiouda T; Domvri K; Boutsikou E; Bikos V; Kyrka K; Papadaki K; Pezirkianidou P; Porpodis K; Cheva A
    J Pers Med; 2024 Apr; 14(5):. PubMed ID: 38793038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting
    Uras IZ; Moll HP; Casanova E
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials.
    Chen W; Li L; Cheng S; Yu J
    Dis Markers; 2022; 2022():2631852. PubMed ID: 36061356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
    Baptiste Oudart J; Garinet S; Leger C; Barlesi F; Mazières J; Jeannin G; Audigier-Valette C; Morot-Sibilot D; Langlais A; Amour E; Mathiot N; Birsen G; Blons H; Wislez M
    Lung Cancer; 2024 Apr; 190():107508. PubMed ID: 38428265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
    Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
    Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
    Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
    [No Abstract]   [Full Text] [Related]  

  • 15. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
    Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
    Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.